BDSI Touts Pain Therapy Pipeline After Emezine "Not Approvable" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioDelivery Sciences International is touting the potential of its flagship analgesic pipeline and downplaying Emezine for severe nausea and vomiting after receiving a "not approvable" letter from FDA Feb. 28 for the latter treatment.